Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome …

Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables
adaptability, limits therapeutic success, and remains incompletely understood. Single-cell …

Mutations play a fundamental role in the development of cancer, and many create targetable
vulnerabilities. There are both public health and basic science benefits from the …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …

PURPOSE BRAFV600 mutations are commonly found in melanoma and thyroid cancers
and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH …

PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and
safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

PURPOSE Microsatellite instability (MSI) and/or mismatch repair deficiency (MMR-D) testing
has traditionally been performed in patients with colorectal (CRC) and endometrial cancer …

CD8+ T cell–dependent killing of cancer cells requires efficient presentation of tumor
antigens by human leukocyte antigen class I (HLA-I) molecules. However, the extent to …

The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the
identification of therapeutic targets, clinical research, and advancing patient care. Because …